Indian Drugs Controller General (DCGI) Dr VG Somani on Tuesday allowed the Serum Institute of India (SII) to resume clinical trials (clinical trials) on candidates for Oxford's Kovid-19 vaccine. DCGI rescinded its earlier order prohibiting the selection of any candidate for the second and third phase trials.
However, DCGI has kept many other conditions including extra attention during the investigation for this. SII has been asked by DGCI to submit information about treatment as per rules in dealing with adverse situations.
Earlier on September 11, DCGI directed the Serum Institute of India to stop the clinical trial of a possible vaccine for Kovid-19 as the pharmaceutical giant Astragenica reported "ill health" of a person involved in the study. The test was later halted in other countries.
(Apart from the headline, this news has not been edited by the NewsBust team, it is published directly from the Syndicate feed.)